Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24 mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole

NCT01207414 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT01207414
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01207414 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-week, Randomized, Multi-center, Open-Label, Iloperidone, (12-24 mg/Day), Flexible Dose Study Assessing Efficacy, Safety and Tolerability of Two Switch Approaches in Schizophrenia Patients Currently Receiving Risperidone, Olanzapine or Aripiprazole
Lead sponsor
Novartis
Phase
Phase 4
Overall status
Completed
Start date
August 31, 2010
Completion date
January 31, 2012
Enrollment
501 (actual)
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia